Publications by authors named "James C-H Yang"

Claim this Profile
E
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.
D Ross Camidge, Shunichi Sugawara, Masashi Kondo, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang

Lung Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer.
Stephanie P L Saw, Wen-Zhao Zhong, Rui Fu, Molly S C Li, Yasushi Goto, James C H Yang

Lung Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amivantamab plus Lazertinib in Previously Untreated -Mutated Advanced NSCLC.
Byoung C Cho, Shun Lu, Enriqueta Felip, Alexander I Spira, Nicolas Girard, James C-H Yang

N Engl J Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.
David Planchard, Pasi A Jänne, Ying Cheng, James C-H Yang, Noriko Yanagitani

N Engl J Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
Julien Mazieres, Paul K Paik, Marina C Garassino, Xiuning Le, Hiroshi Sakai, James C H Yang

JAMA Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice.
Chin Heng Fong, Nicholas Meti, Timothy Kruser, Jessica Weiss, Zhihui Amy Liu, James C H Yang

J Thorac Dis· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
Myung J Ahn, Hye R Kim, James C H Yang, Ji-Yu Han, Jacky Yu-Chung Li

Clin Lung Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
Daniel S W Tan, Sang-We Kim, Santiago Ponce Aix, Lecia V Sequist, Egbert F Smit, James C H Yang

Eur J Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Byoung Chul Cho, Delvys Rodriguez Abreu, Maen Hussein, Manuel Cobo, Anjan J Patel, James Chih Hsin Yang, Xiaoying Yang

Lancet Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
James C H Yang, Marcia S Brose, Gilberto Castro, Edward S Kim, Ulrik N Lassen

BMC Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice.
Paola Anna Jablonska, Chin Heng Fong, Timothy Kruser, Jessica Weiss, Zhihui Amy Liu, James C H Yang

Radiother Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han

J Thorac Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
Keunchil Park, Mustafa Özgüroğlu, Johan Vansteenkiste, David Spigel, James C H Yang

J Thorac Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR tyrosine kinase inhibitors for mutation-positive non-small-cell lung cancer: outcomes in Asian populations.
Edward S Kim, Barbara Melosky, Keunchil Park, Nobuyuki Yamamoto, James C-H Yang

Future Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
Keunchil Park, Mustafa Özgüroğlu, Johan Vansteenkiste, David Spigel, James C-H Yang

Lung Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits and limitations of real-world evidence: lessons from mutation-positive non-small-cell lung cancer.
Bassel Nazha, James C-H Yang, Taofeek K Owonikoko

Future Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential afatinib and osimertinib in patients with mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.
Maximilian J Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang

Future Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han

J Clin Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, James C-H Yang

N Engl J Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.
Daniel S-W Tan, Natasha B Leighl, Gregory J Riely, James C-H Yang, Lecia V Sequist

Lancet Respir Med· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
James C H Yang, Sang-We Kim, Dong-Wan Kim, Jong-Seok Lee, Byoung Chul Cho

J Clin Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Ching-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, Kuan-Yu Chen, Tzu-Hsiu Tsai, James C-H Yang

Eur J Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential afatinib and osimertinib in patients with mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.
Maximilian J Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang

Future Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer.
Rachel Woodford, Yanni Loh, Joanna Lee, Wendy Cooper, Ian Marschner, James C-H Yang

Future Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
Keunchil Park, Jaafar Bennouna, Michael Boyer, Toyoaki Hida, Vera Hirsh, James C-H Yang

Lung Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis